Samuel Andrew Kerk

Samuel Andrew Kerk

Auto-generated profile, based on publicly available information

Samuel Andrew Kerk

Doctoral Program in Cancer Biology, University of Michigan-Ann Arbor

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDaniel M. Kremer
Daniel M. Kremer
BNBarbara S. Nelson
Barbara S. Nelson
LLLin Lin
Lin Lin
EYEmily L. Yarosz
Emily L. Yarosz
CHChristopher J. Halbrook
Christopher J. Halbrook
CLCostas Lyssiotis
Costas Lyssiotis
Cancer metabolism is rewired to support cell survival in response to intrinsic and environmental stressors. Identification of strategies to target these adaptions is an area of active research. We previously described a cytosolic aspartate aminotransaminase (GOT1)-driven pathway in pancreatic cancer used to maintain redox balance. Here, we sought to identify metabolic dependencies following GOT1 inhibition to exploit this feature of pancreatic cancer and to provide additional insight into regulation of redox metabolism. Using pharmacological methods, we identify cysteine, glutathione, and lipid antioxidant function as metabolic vulnerabilities following GOT1 withdrawal. We demonstrate that targeting any of these pathways triggers ferroptosis, an oxidative, iron-dependent form of cell death, in GOT1 knockdown cells. Mechanistically, we reveal that GOT1 inhibition represses mitochondrial metabolism and promotes a catabolic state. Consequently, we find that this enhances labile iron availability through autophagy, which potentiates the activity of ferroptotic stimuli. Overall, our study identifies a biochemical connection between GOT1, iron regulation, and ferroptosis.

9 July 2021 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SKSamuel A. Kerk
Samuel A. Kerk
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
YSYatrik Shah
Yatrik Shah
CLCostas Lyssiotis
Costas Lyssiotis

15 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RSRashi Singhal
Rashi Singhal
SMSreedhar R. Mitta
Sreedhar R. Mitta
NDNupur Das
Nupur Das
SKSamuel A. Kerk
Samuel A. Kerk
PSPeter Sajjakulnukit
Peter Sajjakulnukit
YSYatrik Shah
Yatrik Shah
Hypoxia is a hallmark of solid tumors that promotes cell growth, survival, and metastasis and confers resistance to chemo and radiotherapies. Hypoxic responses are largely mediated by the transcription factors hypoxia-inducible factor 1α (HIF-1α) and HIF-2α. Our work demonstrates that HIF-2α is essential for colorectal cancer (CRC) progression. However, targeting hypoxic cells is difficult, and tumors rapidly acquire resistance to inhibitors of HIF-2α. To overcome this limitation, we performed a small molecule screen to identify HIF-2α–dependent vulnerabilities. Several known ferroptosis activators and dimethyl fumarate (DMF), a cell-permeable mitochondrial metabolite derivative, led to selective synthetic lethality in HIF-2α–expressing tumor enteroids. Our work demonstrated that HIF-2α integrated 2 independent forms of cell death via regulation of cellular iron and oxidation. First, activation of HIF-2α upregulated lipid and iron regulatory genes in CRC cells and colon tumors in mice and led to a ferroptosis-susceptible cell state. Second, via an iron-dependent, lipid peroxidation–independent pathway, HIF-2α activation potentiated ROS via irreversible cysteine oxidation and enhanced cell death. Inhibition or knockdown of HIF-2α decreased ROS and resistance to oxidative cell death in vitro and in vivo. Our results demonstrated a mechanistic vulnerability in cancer cells that were dependent on HIF-2α that can be leveraged for CRC treatment.

21 June 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
ASAndrew J. Schwartz
Andrew J. Schwartz
JGJoshua W. Goyert
Joshua W. Goyert
SSSumeet Solanki
Sumeet Solanki
SKSamuel A. Kerk
Samuel A. Kerk
BCBrandon Chen
Brandon Chen
YSYatrik Shah
Yatrik Shah

11 July 2022 in eLife
Verified
Journal Article
Open access
SKSamuel A Kerk
Samuel A Kerk
LLLin Lin
Lin Lin
AMAmy L Myers
Amy L Myers
DSDamien J Sutton
Damien J Sutton
AAAnthony Andren
Anthony Andren
CLCostas Lyssiotis
Costas Lyssiotis
Mitochondrial glutamate-oxaloacetate transaminase 2 (GOT2) is part of the malate-aspartate shuttle, a mechanism by which cells transfer reducing equivalents from the cytosol to the mitochondria. GOT2 is a key component of mutant KRAS (KRAS*)-mediated rewiring of glutamine metabolism in pancreatic ductal adenocarcinoma (PDA). Here, we demonstrate that the loss of GOT2 disturbs redox homeostasis and halts proliferation of PDA cells in vitro. GOT2 knockdown (KD) in PDA cell lines in vitro induced NADH accumulation, decreased Asp and α-ketoglutarate (αKG) production, stalled glycolysis, disrupted the TCA cycle, and impaired proliferation. Oxidizing NADH through chemical or genetic means resolved the redox imbalance induced by GOT2 KD, permitting sustained proliferation. Despite a strong in vitro inhibitory phenotype, loss of GOT2 had no effect on tumor growth in xenograft PDA or autochthonous mouse models. We show that cancer-associated fibroblasts (CAFs), a major component of the pancreatic tumor microenvironment (TME), release the redox active metabolite pyruvate, and culturing GOT2 KD cells in CAF conditioned media (CM) rescued proliferation in vitro. Furthermore, blocking pyruvate import or pyruvate-to-lactate reduction prevented rescue of GOT2 KD in vitro by exogenous pyruvate or CAF CM. However, these interventions failed to sensitize xenografts to GOT2 KD in vivo, demonstrating the remarkable plasticity and differential metabolism deployed by PDA cells in vitro and in vivo. This emphasizes how the environmental context of distinct pre-clinical models impacts both cell-intrinsic metabolic rewiring and metabolic crosstalk with the TME.

29 May 2020 in Communications Biology
Verified
Journal Article
Open access
ALAndrew Little
Andrew Little
IKIlya Kovalenko
Ilya Kovalenko
LGLaura Elaine Goo
Laura Elaine Goo
HHHanna Sungok Hong
Hanna Sungok Hong
SKSamuel Andrew Kerk
Samuel Andrew Kerk
CLCostas Lyssiotis
Costas Lyssiotis
Metabolic flux technology with the Seahorse bioanalyzer has emerged as a standard technique in cellular metabolism studies, allowing for simultaneous kinetic measurements of respiration and glycolysis. Methods to extend the utility and versatility of the metabolic flux assay would undoubtedly have immediate and wide-reaching impacts. Herein, we describe a platform that couples the metabolic flux assay with high-content fluorescence imaging to simultaneously provide means for normalization of respiration data with cell number; analyze cell cycle distribution; and quantify mitochondrial content, fragmentation state, membrane potential, and mitochondrial reactive oxygen species. Integration of fluorescent dyes directly into the metabolic flux assay generates a more complete data set of mitochondrial features in a single assay. Moreover, application of this integrated strategy revealed insights into mitochondrial function following PGC1a and PRC1 inhibition in pancreatic cancer and demonstrated how the Rho-GTPases impact mitochondrial dynamics in breast cancer.